Oct 27 (Reuters) - The European Medicines Agency (EMA) on Friday said available evidence does not support a causal association between GLP-1 receptor agonist drugs, which include Novo Nordisk's weight loss treatment Wegovy, and thyroid cancer. (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Varun H K)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
917.1 DKK | +0.78% | +3.84% | +31.37% |
05-15 | Health Care Up on Momentum -- Health Care Roundup | DJ |
05-15 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- EU regulator says no direct link between GLP-1 drugs and thyroid cancer